纳曲酮/安非他酮缓释片（Contrave）：肥胖成年人慢性体重管理的新获批治疗选择。
Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults.
作者信息
Sherman Matthew M, Ungureanu Sinziana, Rey Jose A
出版信息
P T. 2016 Mar;41(3):164-72.
Abstract
Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults.
摘要
纳曲酮/安非他酮缓释片（Contrave）：肥胖成年人慢性体重管理新获批的治疗选择。
相似文献
1
2
Naltrexone ER/Bupropion ER: A Review in Obesity Management.纳曲酮长效/安非他酮长效：肥胖症管理中的应用评价。
Drugs. 2015 Jul;75(11):1269-80. doi: 10.1007/s40265-015-0427-5.
3
Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review.Contrave（纳曲酮与安非他酮复方制剂）、纳曲酮、安非他酮或纳曲酮的使用与主要不良心血管事件：一项系统文献综述
Diabetes Metab Syndr Obes. 2022 Sep 29;15:3049-3067. doi: 10.2147/DMSO.S381652. eCollection 2022.
4
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.纳曲酮联合安非他酮对超重和肥胖成年人体重减轻的影响（COR-I）：一项多中心、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29.
5
Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.纳曲酮/安非他酮用于治疗肥胖症及伴有2型糖尿病的肥胖症。
Future Cardiol. 2016 Mar;12(2):129-38. doi: 10.2217/fca.15.79. Epub 2015 Dec 18.
6
Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.Contrave，一种安非他酮和纳曲酮的联合疗法，用于潜在治疗肥胖症。
Curr Opin Investig Drugs. 2009 Oct;10(10):1117-25.
7
Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives.盐酸纳曲酮/盐酸安非他酮用于肥胖成年人的慢性体重管理：患者选择与观点
Patient Prefer Adherence. 2016 May 4;10:751-9. doi: 10.2147/PPA.S84778. eCollection 2016.
8
Perioperative Pain Management of a Patient Taking Naltrexone HCl/Bupropion HCl (Contrave): A Case Report.
A A Case Rep. 2017 Oct 15;9(8):224-226. doi: 10.1213/XAA.0000000000000573.
9
10
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.纳曲酮/安非他酮治疗肥胖的药物安全性评价。
Expert Opin Drug Saf. 2014 Jun;13(6):831-41. doi: 10.1517/14740338.2014.909405. Epub 2014 Apr 28.
引用本文的文献
1
Obesity Epidemic and Its Impact on Female Fertility: Current Understanding and Future Directions.肥胖流行及其对女性生育能力的影响：当前认识与未来方向
Cureus. 2025 Jul 4;17(7):e87283. doi: 10.7759/cureus.87283. eCollection 2025 Jul.
2
The Effectivity and Safety of Naltrexone/Bupropion in Patients Suffering from Overweight and Obesity in a Real-World Setting.纳曲酮/安非他酮在现实环境中对超重和肥胖患者的有效性及安全性
Obes Facts. 2025 Apr 21:1-8. doi: 10.1159/000545967.
3
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss.使用胰高血糖素样肽-1（GLP-1）激动剂减重及维持体重减轻的停药途径。
Biomolecules. 2025 Mar 13;15(3):408. doi: 10.3390/biom15030408.
4
Trial protocol of an open-label pilot study of oral ltrexone-propion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial).口服环丙羟丙甲胺-丙酸联合药物疗法治疗甲基苯丙胺使用障碍的开放标签试点研究试验方案（NABU试验）
BMJ Open. 2025 Feb 7;15(2):e092032. doi: 10.1136/bmjopen-2024-092032.
5
Management of Overweight and Obesity in Patients With Inflammatory Bowel Disease.炎症性肠病患者超重和肥胖的管理
Gastroenterol Hepatol (N Y). 2024 Dec;20(12):712-722.
6
Metabolic/bariatric surgery optimization: a position statement by Arabic association for the study of diabetes and metabolism (AASD).代谢/减重手术优化：阿拉伯糖尿病与代谢研究协会（AASD）的立场声明
Diabetol Metab Syndr. 2025 Jan 29;17(1):37. doi: 10.1186/s13098-024-01564-w.
7
Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review.治疗肥胖并优化育龄女性生育能力的医学疗法：一篇叙述性综述
Reprod Biol Endocrinol. 2025 Jan 6;23(1):2. doi: 10.1186/s12958-024-01339-y.
8
Obesity Medications and Their Impact on Cardiovascular Health: A Narrative Review.肥胖症药物及其对心血管健康的影响：一项叙述性综述
Cureus. 2024 Oct 19;16(10):e71875. doi: 10.7759/cureus.71875. eCollection 2024 Oct.
9
Novel Therapeutic Approach for Obesity: Seaweeds as an Alternative Medicine with the Latest Conventional Therapy.新型肥胖症治疗方法：海藻作为替代医学与最新常规疗法联合应用。
Med Sci (Basel). 2024 Oct 13;12(4):55. doi: 10.3390/medsci12040055.
10
Demographic Data, Risk Factors, and Disease Burden of HS Patients in Lithuania at a Reference Center.立陶宛某参考中心HS患者的人口统计学数据、风险因素及疾病负担
Healthcare (Basel). 2024 Sep 14;12(18):1849. doi: 10.3390/healthcare12181849.
本文引用的文献
1
Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss.纳曲酮/安非他酮用于治疗肥胖症：一种用于减肥的研究性联合药物疗法。
Pharmacol Res. 2014 Jun;84:1-11. doi: 10.1016/j.phrs.2014.04.004. Epub 2014 Apr 19.
2
Prevalence of childhood and adult obesity in the United States, 2011-2012.美国儿童和成人肥胖率，2011-2012 年。
JAMA. 2014 Feb 26;311(8):806-14. doi: 10.1001/jama.2014.732.
3
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.2013年美国心脏协会/美国心脏病学会/肥胖学会成人超重和肥胖管理指南：美国心脏病学会/美国心脏协会实践指南工作组及肥胖学会报告
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2985-3023. doi: 10.1016/j.jacc.2013.11.004. Epub 2013 Nov 12.
4
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.纳曲酮缓释/安非他酮缓释联合疗法对超重和肥胖2型糖尿病患者体重及血糖参数的影响
Diabetes Care. 2013 Dec;36(12):4022-9. doi: 10.2337/dc13-0234. Epub 2013 Oct 21.
5
Why do we need drugs to treat the patient with obesity?为什么我们需要用药物来治疗肥胖症患者？
Obesity (Silver Spring). 2013 May;21(5):893-9. doi: 10.1002/oby.20394.
6
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).纳曲酮缓释/安非他酮缓释片治疗体重和肥胖相关风险因素的随机、3 期临床试验（COR-II）。
Obesity (Silver Spring). 2013 May;21(5):935-43. doi: 10.1002/oby.20309.
7
ACS chemical neuroscience molecule spotlight on contrave.ACS 化学神经科学杂志特写：康百视。
ACS Chem Neurosci. 2011 Sep 21;2(9):484-6. doi: 10.1021/cn200076y.
8
Combination therapy with naltrexone and bupropion for obesity.纳曲酮与安非他酮联合治疗肥胖症。
Expert Opin Pharmacother. 2011 Aug;12(11):1813-26. doi: 10.1517/14656566.2011.591382. Epub 2011 Jun 21.
9
Differential expression and sensitivity of presynaptic and postsynaptic opioid receptors regulating hypothalamic proopiomelanocortin neurons.调节下丘脑促肾上腺皮质素释放激素神经元的突触前和突触后阿片受体的差异表达和敏感性。
J Neurosci. 2011 Jan 5;31(1):281-8. doi: 10.1523/JNEUROSCI.4654-10.2011.
10
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.纳曲酮联合安非他酮对超重和肥胖成年人体重减轻的影响（COR-I）：一项多中心、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29.
Zotero 插件